Emerging Opportunities with Cannabinoids

Table of Contents

• Introduction
• CB1 agonists
  • Cannabinoid agonists and CB1 specific agonists in development
  • Emesis
    • Market size and growth
    • Growth drivers and market risks
    • Current and future drug therapies
  • Cachexia
    • Market size and growth
    • Population forecasts
      • HIV/AIDS cachexia:
      • Forecast number of patients with cachexia associated with HIV/AIDS (' 000s)
      • Cancer cachexia:
    • Growth drivers and market risks
      • HIV/AIDS cachexia:
      • Cancer cachexia:
    • Current and future drug therapies
      • HIV/AIDS cachexia:
      • Cancer cachexia:
  • Pain
    • Market size and growth
      • Neuropathic pain:
      • Population forecasts
      • Growth drivers and market risks
      • Current and future drug therapies
  • Traumatic brain injury
  • Cancer
• CB2 agonists
  • CB2 agonists in development
  • Pain and inflammation
    • Market size and growth
    • Population forecasts
    • Forecast number of patients with osteoarthritis (millions)
  • Growth drivers and market risks
  • Current and future drug therapies
  • Blood cancers
• CB1 antagonists
  • CB1 antagonists in development
  • Obesity
    • Market size and growth
      • Increasing prevalence of obesity in the US
      • Rates of obesity in five major European countries
    • Population forecasts
      • Forecast number of obese adults in millions
    • Growth drivers and market risks
    • Current and future agents
  • Smoking cessation
    • Market size and growth
    • Trends in per capita cigarette consumption
  • Population forecasts
    • Forecast number of smokers (in millions) in major developed markets
  • Growth drivers and market risks
  • Current and future agents
  • Schizophrenia
  • Parkinson' s disease
• CB2 antagonists
• Endocannabi noid deactivation i nhibi tors
  • FAAH inhibitors in development
• Drug p rofiles
  • Acomplia (rimonabant)
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
      • Forecast Acomplia sales by use (US$ millions):
    • Competitor ratio analysis
  • taranabant (MK 0364)
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
      • Forecast taranabant sales by use (US$ millions):
    • Competitor ratio analysis
  • otenabant (CP-945,598)
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
      • Forecast otenabant sales by use (US$ millions):
    • Competitor ratio analysis
  • ibipinabant (BMS-646256; SLV-319)
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
      • Forecast ibipinabant sales by use (US$ millions):
    • Competitor ratio analysis
  • surinabant (SR-147778)
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
  • Marinol (dronabinol)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
    • Marinol Dose: Response Frequency and Adverse Experiences*
    • (N = 750 treatment courses)
  • Cachexia in A IDS patients:
  • Management/clinical expertise
    • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
    • Forecast Marinol sales by use (US$ millions):
  • Competitor ratio analysis
• Cesamet (nabilone)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
    • Forecast Cesamet sales by use (US$ millions):
  • Competitor ratio analysis
• Sativex (tetrahydrocannabinol and cannabidiol)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sativex development overview
  • Sales forecasts and assumptions
    • Forecast Sativex sales by use (US$ millions):
  • Competitor ratio analysis
  • cannabinor (PRS-211,375)
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
  • Competitor ratio analysis
• KN38-7271
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
    • Competitor ratio analysis
  • drinabant (AVE 1625)
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace/gaining share of voice
    • Risks associated with developing a drug within a therapeutic class
    • Filings and approval
    • Sales forecasts and assumptions
    • Competitor ratio analysis
• CRA analysis
  • Methodology
  • Overview
  • Cannabinoid agonists
    • CRA for cannabinoid agonists
  • CB1 antagonists
    • CRA for CB1 antagonists
    • Cannabinoids on the market and in development
• APPEND IX I
  • Abbreviations